Evidence map›Paper›PMID 31370908›Full record

ReviewHuman genomics2019

Next-generation sequencing in liquid biopsy: cancer screening and early detection.

Ming Chen, Hongyu Zhao

4 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 317 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
317citing papers in PubMed, 3 pooled it
17.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05224596 unknown statusnot on this mapstarted 2021, after this paper: background citation

Gastric Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study

TypeobservationalSponsorShanghai Zhongshan HospitalRan2021 to 2022Enrolled498ConditionsCancerArmsBlood draw and blood-based biomarkers analyses
NCT05347524 recruitingnot on this mapstarted 2022, after this paper: background citation

Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study

TypeobservationalSponsorShanghai Zhongshan HospitalRan2022 to 2030Enrolled384ConditionsCancerArmsBaseline blood draw and blood-based biomarkers analyses
NCT05495685 unknown statusnot on this mapstarted 2022, after this paper: background citation

Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study

TypeobservationalSponsorChanghai HospitalRan2022 to 2024Enrolled450ConditionsCancer
NCT05556603 recruitingnot on this mapstarted 2022, after this paper: background citation

Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study

TypeobservationalSponsorRuijin HospitalRan2022 to 2029Enrolled7,062ConditionsCancer
3 · Its place in the literature

Who cites it

317 citing papers in PubMed, 3 syntheses or guidelines pooled it, 563 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

257 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ming ChenDepartment of Biostatistics, School of Public Health, Yale University, New Haven, CT, USA. ming.chen.mc2792@yale.edu.ORCID 0000-0002-7651-4644
Hongyu ZhaoDepartment of Biostatistics, School of Public Health, Yale University, New Haven, CT, USA.
Yale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the rapid development of next-generation sequencing (NGS) technologies has led to a significant reduction in sequencing cost with improved accuracy. In the area of liquid biopsy, NGS has been applied to sequence circulating tumor DNA (ctDNA). Since ctDNA is the DNA fragments released by tumor cells, it can provide a molecular profile of cancer. Liquid biopsy can be applied to all stages of cancer diagnosis and treatment, allowing non-invasive and real-time monitoring of disease development. The most promising aspects of liquid biopsy in cancer applications are cancer screening and early diagnosis because they can lead to better survival results and less disease burden. Although many ctDNA sequencing methods have enough sensitivity to detect extremely low levels of mutation frequency at the early stage of cancer, how to effectively implement them in population screening settings remains challenging. This paper focuses on the application of liquid biopsy in the early screening and diagnosis of cancer, introduces NGS-related methods, reviews recent progress, summarizes challenges, and discusses future research directions.

Indexed as

High-Throughput Nucleotide SequencingBiomarkers, TumorCirculating Tumor DNAEarly Detection of CancerHumansLiquid BiopsyNeoplasmsBiomarkers, TumorCirculating Tumor DNACancer screeningEarly detectionLiquid biopsyNext-generation sequencing

Identifiers

PMID31370908
PMCPMC6669976
OpenAlexW2965555612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.